Mingyue Xia

Jiangsu Key Laboratory For Molecular And Medical Biotechnology
Nanjing, China

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.

Corrigendum: Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.

Journal: Frontiers in oncology

Published: July 12, 2023

Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma.

Rabies virus glycoprotein 29 (RVG29) promotes CAR-T immunotherapy for glioma.

Journal: Translational research : the journal of laboratory and clinical medicine

Published: September 24, 2022

Analysis of N 6 -methyladenosine RNA Modification Levels by Dot Blotting.

Analysis of N 6 -methyladenosine RNA Modification Levels by Dot Blotting.

Journal: Bio-protocol

Published: August 09, 2022

Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.

Inhibition of O-GlcNAc transferase sensitizes prostate cancer cells to docetaxel.

Journal: Frontiers in oncology

Published: July 13, 2022

[Corrigendum] METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.

[Corrigendum] METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.

Journal: International journal of oncology

Published: March 21, 2022

METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.

METTL3 antagonizes 5‑FU chemotherapy and confers drug resistance in colorectal carcinoma.

Journal: International journal of oncology

Published: March 21, 2022

METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis.

METTL3 promotes homologous recombination repair and modulates chemotherapeutic response in breast cancer by regulating the EGF/RAD51 axis.

Journal: eLife

Published: November 03, 2021

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.

Targeting the DNA damage response enhances CD70 CAR-T cell therapy for renal carcinoma by activating the cGAS-STING pathway.

Journal: Journal of hematology & oncology

Published: May 18, 2021

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.

The Role of PARP Inhibitors in the Treatment of Prostate Cancer: Recent Advances in Clinical Trials.

Journal: Biomolecules

Published: March 23, 2021

Showing 1-9 of 9

Last Updated: 09/26/2026